The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
In the latest session, West Pharmaceutical Services, Inc (NYSE: WST) closed at $266.07 down -1.12% from its previous closing price of $269.08. In other words, the price has decreased by -$1.12 from its previous closing price. On the day, 0.51 million shares were traded. WST stock price reached its highest trading level at $271.97 during the session, while it also had its lowest trading level at $265.825.
Ratios:
For a deeper understanding of West Pharmaceutical Services, Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 30.46 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 50.49. For the most recent quarter (mrq), Quick Ratio is recorded 2.18 and its Current Ratio is at 2.87. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In the most recent recommendation for this company, Morgan Stanley on December 02, 2025, initiated with a Equal-Weight rating and assigned the stock a target price of $285.
On September 15, 2025, Rothschild & Co Redburn started tracking the stock assigning a Buy rating and target price of $311.
On June 24, 2025, Barclays started tracking the stock assigning a Equal Weight rating and target price of $245.Barclays initiated its Equal Weight rating on June 24, 2025, with a $245 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, WST now has a Market Capitalization of 19141982208 and an Enterprise Value of 19033032704. As of this moment, West’s Price-to-Earnings (P/E) ratio for their current fiscal year is 39.41, and their Forward P/E ratio for the next fiscal year is 34.22. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.68. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.34 while its Price-to-Book (P/B) ratio in mrq is 6.27. Its current Enterprise Value per Revenue stands at 6.307 whereas that against EBITDA is 23.75.
Stock Price History:
The Beta on a monthly basis for WST is 1.17, which has changed by -0.15442145 over the last 52 weeks, in comparison to a change of 0.12529528 over the same period for the S&P500. Over the past 52 weeks, WST has reached a high of $348.90, while it has fallen to a 52-week low of $187.43. The 50-Day Moving Average of the stock is -2.77%, while the 200-Day Moving Average is calculated to be 11.06%.
Shares Statistics:
For the past three months, WST has traded an average of 697.91K shares per day and 625930 over the past ten days. A total of 71.90M shares are outstanding, with a floating share count of 71.50M. Insiders hold about 0.62% of the company’s shares, while institutions hold 97.89% stake in the company. Shares short for WST as of 1763078400 were 1874904 with a Short Ratio of 2.69, compared to 1760486400 on 1517842. Therefore, it implies a Short% of Shares Outstanding of 1874904 and a Short% of Float of 3.42.
Dividends & Splits
According to the company, the forward annual dividend rate for WST is 0.85, from 0.84 in the trailing year. Against a Trailing Annual Dividend Yield of 0.0031217483. The stock’s 5-year Average Dividend Yield is 0.24. The current Payout Ratio is 12.27% for WST, which recently paid a dividend on 2025-11-12 with an ex-dividend date of 2025-11-12. Stock splits for the company last occurred on 2013-09-27 when the company split stock in a 2:1 ratio.
Earnings Estimates
Currently, 13.0 analysts are dedicated to thoroughly evaluating and rating the performance of West Pharmaceutical Services, Inc (WST) in the stock market.The consensus estimate for the next quarter is $1.65, with high estimates of $1.72 and low estimates of $1.56.
Analysts are recommending an EPS of between $7.24 and $7.02 for the fiscal current year, implying an average EPS of $7.1. EPS for the following year is $7.78, with 16.0 analysts recommending between $8.38 and $7.39.
Revenue Estimates
A total of 11 analysts believe the company’s revenue will be $795.31M this quarter.It ranges from a high estimate of $800M to a low estimate of $790.39M. As of. The current estimate, West Pharmaceutical Services, Inc’s year-ago sales were $748.8MFor the next quarter, 11 analysts are estimating revenue of $759.98M. There is a high estimate of $779.72M for the next quarter, whereas the lowest estimate is $742.81M.
A total of 15 analysts have provided revenue estimates for WST’s current fiscal year. The highest revenue estimate was $3.07B, while the lowest revenue estimate was $3.06B, resulting in an average revenue estimate of $3.06B. In the same quarter a year ago, actual revenue was $2.89BBased on 15 analysts’ estimates, the company’s revenue will be $3.26B in the next fiscal year. The high estimate is $3.34B and the low estimate is $3.22B.
